Carlos Fernández-Carrillo

Dr. Carlos Fernández-Carrillo

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Hepatology Communications
Verified
Journal Article
Open access
EAEdilmar Alvarado
Edilmar Alvarado
DMDavid Martí-Aguado
David Martí-Aguado
CGConcepción Gómez-Medina
Concepción Gómez-Medina
AFAndreu Ferrero-Gregori
Andreu Ferrero-Gregori
JSJustyna Szafranska
Justyna Szafranska
RBRamon Bataller
Ramon Bataller
Background and Aims: Alcohol use disorder has been reported in patients undergoing bariatric procedures, but the pattern of alcohol consumption has not been evaluated. We investigated the prevalence, risk factors, and impact of binge drinking (BD) at the time of surgery and during follow-up. Methods: A prospective, longitudinal study of subjects undergoing bariatric surgery was included in the LABS-2 registry between 2006 and 2009. Participants with AUDIT questionnaire at the time of surgery and a minimum of 12 months follow-up were included. BD was defined as consuming ≥5 drinks on at least 1 occasion in the previous month. Liver biopsies were obtained during bariatric procedures in not all cases. Survival analysis was performed with the adjusted Cox regression model and competing risk. Results: A total of 2257 subjects were included, with a median follow-up of 79 months. The prevalence of BD at time of surgery was 12%, and it raised up to 23% during follow-up. Patients with BD predominantly had a binge eating disorder (OR=1.35 [95% CI: 1.04–1.76]), regularly consumed fast food [OR=1.4 (95% CI: 1.07–1.85)] and used other drugs (OR=2.65 [95% CI: 1.74–4.04]). Within liver biopsies evaluation, BD showed higher hepatic iron deposits (OR=3.00 [95% CI: 1.25–7.21]). BD at the time of surgery was associated with a higher risk of BD during follow-up (OR=10.49 [95% CI: 7.86–14.00]) and long-term mortality (HR: 3.21 [95% CI: 1.67–6.18]). Specific causes of death in these patients with BD were liver disease (p=0.020), suicide (p=0.015), neoplasms (p=0.034), and respiratory (p=0.025). Conclusions: The prevalence of BD in patients undergoing bariatric surgery is high and increases the risk of postoperative liver disease, suicides, and long-term mortality.

7 August 2017 in Liver International
Verified
Journal Article
Open access
PDF file
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
GPGemma Pérez‐Vilaró
Gemma Pérez‐Vilaró
JDJuana Diez
Juana Diez
SPSofía Pérez-del-Pulgar
Sofía Pérez-del-Pulgar
Over the last few years, many reports have defined several types of RNA cell granules composed of proteins and messenger RNA (mRNA) that regulate gene expression on a post‐transcriptional level. Processing bodies (P‐bodies) and stress granules (SGs) are among the best‐known RNA granules, only detectable when they accumulate into very dynamic cytosolic foci. Recently, a tight association has been found between positive‐stranded RNA viruses, including hepatitis C virus (HCV), and these granules. The present article offers a comprehensive review on the complex and paradoxical relationship between HCV, P‐bodies and SGs from a translational perspective. Despite the fact that components of P‐bodies and SGs have assiduously controlled mRNA expression, either by sequestration or degradation, for thousands of years, HCV has learned how to dangerously exploit certain of them for its own benefit in an endless biological war. Thus, HCV has gained the ability to hack ancient host machineries inherited from prokaryotic times. While P‐bodies and SGs are crucial to the HCV cycle, in the interferon‐free era we still lack detailed knowledge of the mechanisms involved, processes that may underlie the long‐term complications of HCV infection.

1 April 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
LMLaura Mensa
Laura Mensa
SPSofía Pérez-del-Pulgar
Sofía Pérez-del-Pulgar
GCGonzalo Crespo
Gonzalo Crespo
GKGeorge Koutsoudakis
George Koutsoudakis
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
XFXavier Forns
Xavier Forns

1 May 2017 in Transplantation
Verified
Journal Article
Closed access
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
GCGonzalo Crespo
Gonzalo Crespo
JRJuan de la Revilla
Juan de la Revilla
LCLluís Castells
Lluís Castells
MBMaria Buti
Maria Buti
MLMaria Carlota Londono
Maria Carlota Londono
Background Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before liver transplant (LT) to eliminate the virus before surgery. However, the unpredictability of donor organ availability may limit treatment duration. Interruption of HCV treatment with resumption post-LT is 1 potential solution which has not been investigated widely. Methods Patients from 5 clinical centers included in the large, national, noninterventional Hepa-C registry who started treatment with direct-acting antiviral agents while awaiting LT were identified retrospectively and followed up prospectively. Fifteen patients who had treatment interruptions around LT were identified. Results The majority of patients (12/15) received interferon-free regimens, most commonly sofosbuvir + daclatasvir (8/12), for a total of 24 weeks (13/15). Treatment was discontinued temporarily for a median of 5 (range, 2-33) days. Fourteen patients completing 12 weeks of follow-up achieved a sustained virological response. One patient who died before week 12 posttreatment achieved a response at posttreatment week 4. Treatment was generally well tolerated. Serious adverse events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose after LT. Conclusions Resumption of direct-acting antiviral agent therapy after a temporary interruption around LT was highly effective, achieving sustained virological response in all patients who completed 12 weeks of posttreatment follow-up. Treatment was generally well tolerated pretransplantation and posttransplantation, with a low rate of serious adverse events. Such a strategy may offer an important new approach to the treatment of patients awaiting LT which may be assessed in future studies.

21 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IHISMAEL EL HAJRA
ISMAEL EL HAJRA
ELElba Llop
Elba Llop
SBSantiago Blanco
Santiago Blanco
CPChristie Perelló
Christie Perelló
CFCarlos Fernández-Carrillo
Carlos Fernández-Carrillo
JCJose Luis Calleja
Jose Luis Calleja
Background: Multiple studies have linked COVID-19 to a higher incidence of thromboembolic disorders. However, the association of COVID-19 with other potentially life-threatening complications, such as splanchnic vein thrombosis, is less well understood. This study aims to assess the prevalence, patient characteristics, clinical presentation, and outcomes of patients with portal vein thrombosis (PVT) and COVID-19. Methods: This was a retrospective observational study. From all positive patients for a reverse-transcription polymerase chain reaction (RT-PCR) swab test from March 2020 to June 2020, we included those who were older than 18 years, had received abdominal contrast-enhanced computed tomography (CT) in the 6 months following the positive RT-PCR swab, and had no previously known splanchnic vein thrombosis. Results: A total of 60 patients with abdominal CT were selected from all those positive for SARS-CoV-2 (n = 2987). The prevalence of PVT was 3/60 (5%). The mean age was 66.1 ± 16.5 years and 51.7% were male. In two of the three patients, there was no underlying pathology as a risk factor for PVT and one of them presented cirrhosis. The number of days from the start of COVID-19 symptoms until the PVT diagnosis were 21, 12, and 10 days. Anticoagulation treatment achieved recanalization in 100% of cases. During a mean follow-up of 803 days, none of the patients experienced long-term complications. Conclusions: Portal vein thrombosis is uncommon, and its incidence may be higher in COVID-19 patients. A greater understanding of the features of this disease in the context of COVID-19 could aid towards its diagnosis and allow for early detection and management.

1 April 2015 in Journal of Hepatology
Verified
Journal Article
Closed access
MPM. Prieto
M. Prieto
MLM. Carlota Londoño
M. Carlota Londoño
JPJ.M. Pascasio
J.M. Pascasio
MSM. Salcedo
M. Salcedo
JCJavier Crespo
Javier Crespo
XFX. Forns
X. Forns